### Session: P-09. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

**Background.** A new therapeutic monitoring of vancomycin for serious methicillin resistant *Staphylococcus aureus* infections guideline was published in March 2020. The guideline recommends a change in monitoring from trough to AUC/MIC based to improve patient outcomes. The purpose of this study was to determine institutional uptake of vancomycin AUC monitoring 1-year post guideline publication in hospitals across the US.

Methods. An electronic survey was created to assess vancomycin AUC monitoring practices and distributed to the American College of Clinical Pharmacy Infections Diseases Practice and Research Network (ACCP IDprn) and American Society of Health System Pharmacists (ASHP). Initial survey distribution (phase 1) occurred May-June 2020 and aimed to serve as baseline data. The survey was re-distributed (phase 2) to the ACCP IDprn and ASHP one year later, May-June 2021. Prior to re-distribution the survey was updated to assess the impact of COVID-19 on uptake. Results were analyzed and reported using descriptive statistics. Chi-Square tests were used to compare categorical data.

**Results.** A total of 202 responses to phase 1 and 138 responses to phase 2 were recorded. Significantly more respondents implemented AUC monitoring 1-year post guideline than at baseline (42.8% vs 29.8%, p= 0.013). In both phases, 57% of those who had not implemented AUC monitoring had plans to do so over the next year. Additionally, 46.2% phase 2 respondents reported COVID-19 impacted their ability to transition to AUC monitoring citing issues such as lack of time and inadequate resources. The most common AUC monitoring programs utilized at baseline and 1-year post guideline were purchased Bayesian software (38.3% vs. 35.6%) and home-made software (26.1% vs 23.7%). Perceived challenges to implementing AUC monitoring included cost, difficult use and integration.

**Conclusion.** Increased uptake of vancomycin AUC monitoring occurred from baseline to 1-year post guideline publication. However, less than half of hospitals implemented this recommendation. Although COVID-19 impacted a large portion respondents' ability to implement AUC monitoring, majority plan to transition to vancomycin AUC monitoring over the next year. AUC monitoring should be adapted by all hospitals to optimize vancomycin efficacy and safety.

Disclosures. All Authors: No reported disclosures

# 176. Topical Antibiotic and Antiseptic Use in the Operating Room: An Opportunity for Antimicrobial Stewardship?

Joséf Hadib Nissan, PharmD<sup>1</sup>; Nina Naeger Murphy, PharmD, BCPS-AQ ID<sup>2</sup>; Nilam Patel, PharmD<sup>1</sup>; Mary Borovicka, PharmD<sup>1</sup>; Michelle Hecker, MD<sup>3</sup>; David Gothard, PhD<sup>1</sup>; <sup>1</sup>The MetroHealth System, Cleveland, Ohio; <sup>2</sup>MetroHealth Medical Center, Cleveland, Ohio; <sup>3</sup>Metro Health Medical Center, Cleveland, OH

### Session: P-09. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

**Background.** Data suggest that topical antibiotic and antiseptic use in the operating room is common but not commonly monitored by antimicrobial stewardship programs. Although some data suggest a benefit in certain surgical procedures, the CDC and WHO advise against the routine use of topical antibiotics in surgery due to uncertainty and heterogeneity in the overall data.

Methods. We conducted a retrospective 28-day period prevalence study of topical antibiotic and antiseptic use during surgical procedures performed in the operating room by 6 surgical specialties at a tertiary care medical center. For the subset of patients undergoing orthopedic surgeries, we evaluated the types of topical antibiotics received and the rates of surgical site infections (SSI) and adverse drug events within 28 days of the procedure.

**Results.** Of 744 surgical procedures reviewed, topical antibiotics were used in 127 (17.1%), topical antiseptics in 71 (9.5%), and both in 18 (2.4%) (Table 1). Antiseptic use was higher in orthopedics relative to all other surgical specialties while topical antibiotic use was higher in neurosurgery. Hand, vascular and plastics had distinguishably lower use. In the orthopedic subgroup, after exclusions, 218 procedures were evaluated. Topical antibiotics were used in 42 (19.2%). Topical antibiotic therapy was more likely to be administered if prosthetic material was implanted, the procedure was emergent, or if a *Staphylococcus aureus* infection was present. Vancomycin was the most commonly used topical antibiotic and powder was the most commonly used type of application. As shown in table 2, SSI occurred more often when both topical antibiotics and antiseptics were expliced, however, SSI events were relatively uncommon, and these were more likely to have infection present at the time of surgery. Adverse events were rare.

Table 1: Prevalence of topical antibiotic and antiseptic use by surgical specialty, No. (%)

Surgical specialty	Number of procedures	Use of topical antibiotics	Use <u>of topical</u> antiseptics	Use of both	Use of none	
		(alone or with	(alone or with			
		topical antiseptics)	topical antibiotics)			
All services	744	127 (17.1)	71 (9.5)	18 (2.4)	564 (75.8)	
Orthopedics	239	52 (21.8)	48 (20.1)	8 (3.3)	147 (61.5)	
Podiatry	44	4 (9.1)	8 (18.2)	1 (2.3)	33 (75.0)	
Neurosurgery	137	68 (49.6)	9 (6.6)	9 (6.6)	69 (50.4)	
Hand	125	0 (0)	5 (4.0)	0 (0)	120 (96.0)	
Vascular	79	2 (2.5)	0 (0)	0 (0)	77 (97.5)	
Plastics	120	1 (0.8)	1 (0.8)	0 (0)	118 (98.3)	

Table 2: Clinical outcomes within 28 days of procedure, No. (%)

	Number of procedures (n=218)	Topical antibiotic alone (n=42)	Topical antiseptic alone (n=36)	Both (n=11)	None (n=129)	P-value
Surgical site infection	9 (4.1)	3 (7.1)	0	3 (27.3)	3 (2.3)	0.004
Adverse event	2 (0.9)	0	1 (2.9)	0	1 (0.8)	0.424

**Conclusion.** In our institution we noted significant variability in use of topical antibiotic and antiseptic therapy among surgical specialties as well as within the orthopedic surgical specialty. Although opportunities to standardize use/nonuse of these therapies exist, this may be challenging due to the uncertainty and heterogeneity of currently available data.

Disclosures. All Authors: No reported disclosures

## 177. User Preferences for Visualization of Antibiogram Data in Clinical Practice for Empiric Prescription of Antibiotics

Alexandria R. Vingino, MPH<sup>1</sup>; Peter Rabinowitz, MD, MPH<sup>2</sup>; Hema Kapoor, MD; D(ABMM)<sup>3</sup>; Vickie Ramirez, MA<sup>1</sup>; Ann Salm, M (ASCP), MSc, PhD<sup>1</sup>; <sup>1</sup>University of Washington - Center for One Health Research, Seattle, Washington; <sup>2</sup>University of Washington, Seattle, WA; <sup>3</sup>Quest Diagnostics, Secaucus, New Jersey; <sup>4</sup>Quest Diagnostics, Incorporated, Secaucus, New Jersey

#### Session: P-09. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

**Background.** Antibiograms are widely used to present antibiotic susceptibility data, but user preferences for data visualization have received little attention. We report on a qualitative research study designed to gauge preferences for presenting antibiotic resistance data, with the goals of improving speed and effectiveness of prescribing empiric antibiotics in out-patient practices to meaningfully influence antibiotic steward-ship programs.

**Methods.** Criteria for online focus groups included having the ability to prescribe antibiotics, practice in Washington state, and familiarity with antibiogram usage. A preliminary survey (Fig. 1) was sent to selected participants to understand their role in healthcare and their current attitudes towards antibiograms. During focus groups, we presented examples of 3 antibiograms: standard (Fig. 2A), color-coded for % susceptible (Fig. 2B), and color-coded for change in % susceptible from 2013 to 2016 (Fig. 2C).

### Figure 1. Preliminary Survey via RedCap

Confidential

### Antibiogram General Use (Preliminary Survey)

Please complete the survey below Thank you!

Name (Last, first)

Hello! Thank you for agreeing to participate in our focus group discussion on antibiogram data

visualization. This preliminary survey contains 11 questions and should take about 10 minutes. This survey will help tailor our focus group discussion based on your responses.

Thank you for your time! If you have any questions before our meeting, please feel free to email me at avingi@uw.edu

Name of your facility			
Job title			
Do you have an administrative role in infection prevention and/or antibiotic stewardship?	⊖ Yes ⊖ No		
Do you see patients at this clinic?	⊖ Yes ○ No		
Does your clinic have inpatient care, outpatient care, or other?	Inpatient care Outpatient care Other		
Other			
Do you prescribe antibiotics for urinary tract infections?	⊖ Yes ⊖ No		
What resources do you use for empiric antibiotic choices in urinary tract infections?	☐ Sanford Guide ☐ Up-to-Data ☐ Antibiogram data ☐ Other		
Other			
Do you use antibiogram data to help make antibiotic choices?	○ Yes ○ No		
If yes, how do you use antibiogram data to make antibiotic choices?			
If no, why not?			

05/17/2021 4:53pm

projectredcap.org

Page 1

A preliminary survey via RedCap was sent all focus group participants to capture current attitudes towards antibiograms and antibiotic resistance data.